New drug MGC026 takes on advanced cancers in first human trial
NCT ID NCT06242470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive up to 35 doses if their cancer does not worsen and side effects are manageable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MGC026 (a biologic drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for several advanced cancers that have stopped responding to other therapies.
- What could go wrong
- This is a very early Phase 1 trial, so the main goal is safety, not proof of effectiveness. Many drugs fail at this stage, and side effects could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Health- Olivia Newton John Cancer Center
RECRUITINGHeidelberg, Victoria, 3084, Australia
-
ICON Cancer Centre Kurralta Park
RECRUITINGKurralta Park, South Australia, 5037, Australia
-
ICON Cancer Centre Wesley
RECRUITINGAuchenflower, Queensland, 4066, Australia
-
Oxford University Hospitals NHS Foundation Trust
RECRUITINGOxford, OX3 9DU, United Kingdom
-
Providence Cancer Institute
RECRUITINGPortland, Oregon, 97213, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
START-New York Long Island
RECRUITINGLake Success, New York, 11042, United States
-
The Angeles Clinic and Research Institute
RECRUITINGLos Angeles, California, 90025, United States
-
The Royal Marsden NHS Foundation Trust
RECRUITINGSutton, SM2 5PT, United Kingdom
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of Texas Health Science Center at Houston
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new protein drug shield kids with cancer from dangerous infections?
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A safer first cut? trial tests two laparoscopic entry points for endometrial cancer surgery